Indicators
Indicators
Value
Direction
MACD(12,26,9)
0.079
Buy
RSI(14)
55.918
Neutral
STOCH(KDJ)(9,3,3)
64.195
Sell
ATR(14)
0.295
Low Volatility
CCI(14)
69.894
Neutral
Williams %R
21.212
Buy
TRIX(12,20)
0.309
Sell
StochRSI(14)
0.000
Sell
Fennec Pharmaceuticals Inc
FENC9.075USD
+0.065+0.72%
Market hours （ET）Quotes delayed by 15 min
251.68MMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score
Currency: USD Updated：2025-09-10Key Insights
The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a weak stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Score
Support & Resistance
No Data
Score Analysis
Current score
Previous score
Analyst Rating
Based on
5
analysts
Buy
Current Rating
13.800
Target Price
+53.16%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Company Highlights
StrengthsRisks
Fennec Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on its product candidate PEDMARK. It sells its product through a field force, including Regional Pediatric Oncology Specialists and medical science liaisons who are helping to educate the medical communities and patients about cisplatin induced ototoxicity and its programs supporting patient access to PEDMARK. PEDMARK is a Food and Drug Administration approved therapy indicated to reduce the risk of ototoxicity associated with cisplatin treatment in pediatric patients with localized, non-metastatic, solid tumors. It is a formulation of sodium thiosulfate in single-dose, ready-to-use vials for intravenous use in pediatric patients. PEDMARK is a therapeutic agent with a dosing paradigm, across two open-label, randomized Phase 3 clinical studies, the Clinical Oncology Group (COG) Protocol ACCL0431 and SIOPEL 6. It has established Fennec HEARS, a single source program designed to connect PEDMARK patients.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 2996.94% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 47.54M.
Undervalued
The company’s latest PE is -20.50, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 20.52M shares, decreasing 11.24% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 967.09K shares of this stock.
Financial Health
Currency: USD Updated：2025-09-10The company's current financial score is 8.21, which is higher than the Pharmaceuticals industry's average of 6.80. Its financial status is robust, and its operating efficiency is average. Its latest quarterly revenue reached 8.75M, representing a year-over-year decrease of 65.52%, while its net profit experienced a year-over-year decrease of 109.08%.
Score
Financials
10.00
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
No Data
Quality of Earnings
9.40
Operational Efficiency
7.39
Growth Potential
7.18
Shareholder Returns
7.10
Company Valuation
Currency: USD Updated：2025-09-10The company’s current valuation score is 1.20, which is lower than the Pharmaceuticals industry's average of 1.64. Its current P/E ratio is -20.57, which is -58.35% below the recent high of -8.57 and 23.74% above the recent low of -15.68.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 11/177
No Data
Earnings Forecast
Currency: USD Updated：2025-09-10The company’s current earnings forecast score is 8.80, which is higher than the Pharmaceuticals industry's average of 7.96. The average price target for Fennec Pharmaceuticals Inc is 13.00, with a high of 15.00 and a low of 13.00.
Score
Support & Resistance
No Data
Analyst Rating
Based on
5
analysts
Buy
Current Rating
13.800
Target Price
+53.16%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
179
Total
5
Median
8
Average
Company name
Ratings
Analysts
Fennec Pharmaceuticals Inc
FENC
5
Biogen Inc
BIIB
35
Amgen Inc
AMGN
34
Vertex Pharmaceuticals Inc
VRTX
32
Alnylam Pharmaceuticals Inc
ALNY
32
Eli Lilly and Co
LLY
31
1
2
3
...
36
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
No Data
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated：2025-09-10The company’s current price momentum score is 9.25, which is higher than the Pharmaceuticals industry's average of 6.80. Sideways: Currently, the stock price is trading between the resistance level at 9.92 and the support level at 7.67, making it suitable for range-bound swing trading.
Score
Support & Resistance
No Data
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
9.086
Sell
MA10
8.998
Buy
MA20
8.716
Buy
MA50
8.614
Buy
MA100
7.916
Buy
MA200
7.033
Buy
Institutional Confidence
Currency: USD Updated：2025-09-10The company’s current institutional recognition score is 7.00, which is higher than the Pharmaceuticals industry's average of 6.02. The latest institutional shareholding proportion is 74.29%, representing a quarter-over-quarter increase of 0.30%. The largest institutional shareholder is The Vanguard, holding a total of 967.09K shares, representing 3.47% of shares outstanding, with 2.21% decrease in holdings.
Score
Institutional Shareholding
No Data
Shareholder Activity
Name
Shares Held
Chg %
Southpoint Capital Advisors LP
ESSETIFIN S.p.A.
Sonic GP LLC
Solas Capital Management, LLC
Rosalind Advisors, Inc.
BlackRock Institutional Trust Company, N.A.
State Street Global Advisors (US)
AIGH Capital Management, LLC.
Geode Capital Management, L.L.C.
1
2
Risk Assessment
Currency: USD Updated：2025-09-10The U.S. Dollar Index is currently in a neutral state, which has a minor effect on the Pharmaceuticals mixed industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The company’s current risk assessment score is 5.36, which is higher than the Pharmaceuticals industry's average of 3.51. The company's beta value is 0.58. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.
Score
Beta vs S&P 500 index
0.63
VaR
+5.06%
240-Day Maximum Drawdown
+28.63%
240-Day Volatility
+69.57%
Return
Best Daily Return
60 days
+12.00%
120 days
+12.00%
5 years
+15.78%
Worst Daily Return
60 days
-6.37%
120 days
-9.20%
5 years
-50.41%
Sharpe Ratio
60 days
+1.23
120 days
+1.72
5 years
+0.38
Risk Assessment
Maximum Drawdown
240 days
+28.63%
3 years
+65.63%
5 years
+65.63%
Return-to-Drawdown Ratio
240 days
+2.81
3 years
+0.06
5 years
+0.05
Skewness
240 days
+0.21
3 years
-0.36
5 years
-2.35
Volatility
Realised Volatility
240 days
+69.57%
5 years
+69.80%
Standardised True Range
240 days
+4.02%
5 years
+4.17%
Downside Risk-Adjusted Return
120 days
+302.29%
240 days
+302.29%
Maximum Daily Upside Volatility
60 days
+32.49%
Maximum Daily Downside Volatility
60 days
+47.06%
Liquidity
Average Turnover Rate
60 days
+0.24%
120 days
+0.31%
5 years
--
Turnover Deviation
20 days
-40.08%
60 days
-38.98%
120 days
-22.51%
Peer Comparison
Currency: USD Updated：2025-09-10Fennec Pharmaceuticals Inc
FENC
7.07 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Royalty Pharma PLC
RPRX
7.67 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Neurocrine Biosciences Inc
NBIX
7.56 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
United Therapeutics Corp
UTHR
7.41 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
BridgeBio Pharma Inc
BBIO
7.33 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Biogen Inc
BIIB
7.29 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
The Stock Score data is powered by TradingKey and updated daily. Rating data is sourced from LESG. Please use the data with caution for reference purposes only.
